Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 12 EP applications Rie Jewson has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 22, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12738465

BICYCLIC PYRIMIDONE COMPOUNDS

IPC classification:
A61K 31/519, C07D 487/04, A61P 25/28
Applicant:
Glaxo Group Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12818124

2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA INHIBITORS

IPC classification:
A61K 31/519, C07D 487/04, A61P 25/28, A61P 9/10
Applicant:
Glaxo Group Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12756693

NOVEL CRYSTAL FORM

IPC classification:
A61K 31/4545, C07D 401/12, A61P 25/28
Applicant:
Glaxo Group Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14701355

2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS

IPC classification:
A61K 31/519, C07D 487/04, A61P 25/28
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
The patent has been granted
EP14743409

COMPOUNDS

IPC classification:
A61K 31/519, C07D 487/04, A61P 25/28, A61P 25/16, A61P 25/14
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14743086

BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2

IPC classification:
A61K 31/519, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP11847368

COMPOUNDS

IPC classification:
C07D 403/06, C07D 239/52, C07D 213/69, C07D 401/12, C07D 401/14, A61P 9/10, A61K 31/513, A61K 31/4412, C07D 401/06
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11802872

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2

IPC classification:
C07D 417/06, C07D 413/06, C07D 403/14, C07D 403/12, C07D 403/06, C07D 401/14, C07D 401/12, C07D 401/06, C07D 239/56, C07D 239/52, C07D 239/47, C07D 239/36
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15702008

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

IPC classification:
A61P 43/00, C07D 307/68, C07D 307/24, A61K 31/431, C07D 407/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP16827267

COMPOUNDS

IPC classification:
A61P 25/16, A61K 31/416, C07D 231/56
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
Request for examination was made
EP17194953

IMPROVED ANTI-SERUM ALBUMIN BINDING VARIANTS

IPC classification:
C07K 14/575, C07K 14/56, C07K 16/28, C07K 16/18
Applicant:
Glaxo Group Limited
Agent:
Rie Jewson, GlaxoSmithKline
Status:
Request for examination was made
EP18161541

ACE2 POLYPEPTIDE

IPC classification:
C07K 14/705, A61K 38/48, C12N 9/64
Applicant:
Apeiron Biologics AG
Agent:
Rie Jewson, GlaxoSmithKline
Status:
The application has been published

Please Sign in to use this feature